• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟喹诺酮类抗生素:该类及各药物的特性

Fluoroquinolone antibiotics: properties of the class and individual agents.

作者信息

Stratton C

机构信息

Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee.

出版信息

Clin Ther. 1992 May-Jun;14(3):348-75; discussion 347.

PMID:1638577
Abstract

The broad spectrum of activity and bactericidal nature of the fluoroquinolones, together with their excellent absorption, rapid distribution, and high tissue concentration, make them excellent therapeutic agents for the management of a number of complicated community-acquired and nosocomial infections of the urinary tract, bone and soft tissue, gastrointestinal tract, and prostate, as well as some respiratory tract infections and sexually transmitted diseases. Data are presented and reviewed concerning the in vitro activity, pharmacology, and clinical use of ciprofloxacin, norfloxacin, and ofloxacin, which have been available for some time, and lomefloxacin and temafloxacin, which are recently approved agents. The comparable qualities and differences in activity and clinical applications of these agents are considered. For many infections in selected patients, quinolones are excellent substitutes for parenteral agents. In general, adverse effects have been infrequent and rarely require drug discontinuation. Significant interactions, such as with theophylline and caffeine, have occurred but are quinolone dependent. Antacids can markedly impair the absorption of all quinolones. Because emerging resistance to Pseudomonas and Staphylococcus species have been observed, the improper use of the quinolones must be avoided, and the clinician must be aware that an unfavorable response may signal resistance. The development of future agents with better gram-positive activity, improved gram-negative coverage, and activity against unusual pathogens such as Chlamydia species and Mycobacterium species, will make these oral agents invaluable. Assessing the usefulness and safety of these antibiotics in children is an ongoing challenge.

摘要

氟喹诺酮类药物具有广泛的抗菌活性和杀菌特性,再加上其吸收良好、分布迅速且组织浓度高,使其成为治疗多种复杂的社区获得性和医院内感染的理想药物,这些感染包括泌尿系统、骨骼和软组织、胃肠道、前列腺感染,以及一些呼吸道感染和性传播疾病。本文展示并综述了环丙沙星、诺氟沙星和氧氟沙星(已上市一段时间)以及洛美沙星和替马沙星(最近获批的药物)的体外活性、药理学和临床应用数据。文中还考虑了这些药物在活性和临床应用方面的相似之处和差异。对于特定患者的许多感染,喹诺酮类药物是胃肠外用药的理想替代品。总体而言,不良反应并不常见,很少需要停药。虽然已经出现了与茶碱和咖啡因等药物的显著相互作用,但这取决于喹诺酮类药物的种类。抗酸剂会显著损害所有喹诺酮类药物的吸收。由于已观察到对铜绿假单胞菌和葡萄球菌属出现新的耐药性,必须避免喹诺酮类药物的不当使用,临床医生必须意识到不良反应可能表明出现了耐药性。开发具有更好的革兰氏阳性菌活性、更强的革兰氏阴性菌覆盖范围以及对衣原体属和分枝杆菌属等不常见病原体有活性的新型药物,将使这些口服药物具有极高的价值。评估这些抗生素在儿童中的有效性和安全性仍然是一项持续的挑战。

相似文献

1
Fluoroquinolone antibiotics: properties of the class and individual agents.氟喹诺酮类抗生素:该类及各药物的特性
Clin Ther. 1992 May-Jun;14(3):348-75; discussion 347.
2
Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.
Clin Pharm. 1992 Sep;11(9):753-66.
3
The role of the fluoroquinolones.氟喹诺酮类药物的作用。
Pharmacotherapy. 1992;12(6 Pt 2):71S-85S.
4
The place of quinolones in bacterial infections.喹诺酮类药物在细菌感染中的地位。
Adv Intern Med. 1991;36:1-32.
5
Enoxacin: a new fluoroquinolone.
Clin Pharm. 1989 Feb;8(2):97-107.
6
Overview of the fluoroquinolone antibiotics.氟喹诺酮类抗生素概述。
Pharmacotherapy. 1993 Mar-Apr;13(2 Pt 2):4S-17S.
7
Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.芦氟沙星(MF - 934):体内外抗菌活性
Drugs Exp Clin Res. 1989;15(1):11-5.
8
Do we need an intravenous fluoroquinolone?我们需要静脉注射氟喹诺酮类药物吗?
West J Med. 1992 Jul;157(1):55-9.
9
Fluoroquinolones: how to use (but not overuse) these antibiotics.氟喹诺酮类药物:如何使用(但不要过度使用)这些抗生素。
Geriatrics. 1993 Jun;48(6):41-4, 49-51.
10
Quinolones: a comprehensive review.喹诺酮类药物:全面综述。
Am Fam Physician. 2002 Feb 1;65(3):455-64.

引用本文的文献

1
Square-wave adsorptive anodic stripping voltammetric determination of norfloxacin using a glassy carbon electrode modified with carbon black and CdTe quantum dots in a chitosan film.采用碳黑和 CdTe 量子点修饰壳聚糖修饰玻碳电极,建立了方波吸附溶出伏安法测定诺氟沙星的新方法。
Mikrochim Acta. 2019 Feb 2;186(3):148. doi: 10.1007/s00604-019-3268-1.
2
Magnetically stimulated ciprofloxacin release from polymeric microspheres entrapping iron oxide nanoparticles.磁性刺激包裹氧化铁纳米颗粒的聚合物微球释放环丙沙星。
Int J Nanomedicine. 2015 Jul 9;10:4447-58. doi: 10.2147/IJN.S82830. eCollection 2015.
3
Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option.
尿路感染管理中的当前问题:缓释环丙沙星作为一种新型治疗选择。
Drugs. 2004;64(6):611-28. doi: 10.2165/00003495-200464060-00004.
4
Urinary tract infections in adult general practice patients.成年全科门诊患者的尿路感染
Br J Gen Pract. 2002 Sep;52(482):752-61.
5
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.静脉注射/口服环丙沙星联合甲硝唑与哌拉西林/他唑巴坦治疗复杂性腹腔内感染的比较
Ann Surg. 2000 Aug;232(2):254-62. doi: 10.1097/00000658-200008000-00016.
6
Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.一项比较环丙沙星加甲硝唑序贯静脉/口服治疗与亚胺培南/西司他丁治疗腹腔内感染的随机试验结果。腹腔内感染研究组。
Ann Surg. 1996 Mar;223(3):303-15. doi: 10.1097/00000658-199603000-00012.
7
Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.口服氟罗沙星在菌血症患者中的单剂量药代动力学
Antimicrob Agents Chemother. 1994 Jun;38(6):1219-24. doi: 10.1128/AAC.38.6.1219.
8
Intracellular concentrations of antibacterial agents and related clinical implications.抗菌药物的细胞内浓度及其相关临床意义。
Clin Pharmacokinet. 1994 Jul;27(1):63-84. doi: 10.2165/00003088-199427010-00006.